Perspective Therapeutics (NYSEAMERICAN:CATX) Releases Earnings Results, Beats Expectations By $0.04 EPS

Perspective Therapeutics (NYSEAMERICAN:CATX) announced its quarterly earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04, FiscalAI reports. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.16 million.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded up $0.12 during mid-day trading on Monday, reaching $3.88. The stock had a trading volume of 1,133,459 shares, compared to its average volume of 2,837,001. The company has a 50-day moving average price of $4.56 and a two-hundred day moving average price of $3.58. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17.

Analyst Ratings Changes

Several research firms have weighed in on CATX. UBS Group lifted their price objective on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Piper Sandler began coverage on Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target on the stock. Truist Financial set a $12.00 price objective on Perspective Therapeutics in a report on Tuesday, March 17th. HC Wainwright boosted their target price on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $12.63.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $28,000. Russell Investments Group Ltd. raised its holdings in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the last quarter. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the 4th quarter worth approximately $31,000. Engineers Gate Manager LP bought a new position in Perspective Therapeutics in the 4th quarter valued at approximately $35,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Perspective Therapeutics in the 4th quarter valued at approximately $42,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.